ArticleScientific reports2025
Total flavonoids of rhizoma drynariae improved the osteogenic and pro-angiogenic capacities of BMSCs to accelerate long bone regeneration.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Total Flavonoids of Rhizoma Drynariae (TFRD) possess the ability to enhance bone regeneration by promoting angiogenesis-osteogenesis coupling, but the underlying mechanisms remain poorly understood. This study aimed to investigate the influence of TFRD on the coordination of osteogenic and pro-angiogenic properties of bone marrow mesenchymal stem cells (BMSCs) during long bone regeneration and further elucidate the underlying mechanism. We initially assessed pharmacological effects of TFRD in mouse monocortical tibial defect (MTD) model by utilizing micro-CT, histopathology and immunofluorescence imaging. Subsequently, we extracted BMSCs from TFRD-treated mice and characterized the regulatory effects of TFRD on the behavior of BMSCs. We observed that TFRD treatment increased skeletal parameters, osteoblast number, vessel volume and perivascular osteoprogenitor population within the callus. In vitro analyses revealed that TFRD promoted the proliferation and osteogenic differentiation of BMSCs. Additionally, BMSC-conditioned medium from TFRD-treated mice enhanced the migration, proliferation and tube formation of endothelial cells (ECs) under hypoxia. TFRD increased the expression level of HIF-1α and its target genes in callus and hypoxia-cultured ECs. The results of YAP1/TAZ interference in ECs by using siRNA indicated that the enhancement of HIf-1α was through YAP1/TAZ inhibition. Our findings suggest that YAP1/TAZ/ HIf-1α pathways involved in indirect regulation of TFRD on angiogenesis through BMSCs paracrine pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.